Utility of diffusion-weighted MRI for assessing liver fibrosis in patients with chronic active hepatitis

Diagnostic and Interventional Radiology

Volumn 16, Issue 3, 2010, Pages 204-208

  Soylu, Aliye ^a   Kilçkesmez, Özgür ^c   Poturoǧlu, Şule ^a   Dolapçioǧlu, Can ^e   Serez, Kemal ^d   Sevindir, Isa ^b   Yaşar, Nurgül ^b   Akyildiz, Murat ^a   Kumbasar, Baki ^d  

^a Institute of Gastroenterology   (Turkey)

^b Internal Medicine   (Turkey)

^c YEDITEPE UNIVERSITY   (Turkey)

^d HASEKI EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^e Kartal Training and Research Hospital   (Turkey)

Author keywords

Chronic hepatitis; Diffusion weighted magnetic resonance imaging; Liver fibrosis

Indexed keywords

GADOLINIUM PENTETATE MEGLUMINE;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFUSION WEIGHTED IMAGING; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; NONALCOHOLIC FATTY LIVER; PROSPECTIVE STUDY; SCORING SYSTEM; VOLUNTEER;

BIOPSY; DIFFUSION MAGNETIC RESONANCE IMAGING; HEPATITIS, CHRONIC; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LIVER; LIVER CIRRHOSIS; REFERENCE VALUES;

EID: 77957231232     PISSN: 13053825     EISSN: 13053612     Source Type: Journal    
DOI: 10.4261/1305-3825.DIR.2810-09.1     Document Type: Article

References (47)

1. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39:1147-1171.
2. Kim AI, Saab S. Treatment of hepatitis C. Am J Med 2005; 118:808-815.
3. Gish RG. Current treatment and future directions in the management of chronic hepatitis B viral infection. Clin Liver Dis 2005; 9:541-565.
4. Tobkes AI, Nord HJ. Liver biopsy: review of methodology and complications. Dig Dis 1995; 13:267-274.
5. Janes CH, Lindor KD. Outcome of patients hospitalized for complications after outpatient liver biopsy. Ann Intern Med 1993; 118:96-98.
6. Froehlich F, Lamy O, Fried M, Gonvers JJ. Practice and complications of liver biopsy: results of a nationwide survey in Switzerland. Dig Dis Sci 1993; 38:1480-1484.
7. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. Hepatology 2000; 32:477-481.
8. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97:2614-2618.
9. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38:1449-1457.
10. Afdhal NH, Nunes D. Evaluation of liver fi-brosis: a concise review. Am J Gastroenterol 2004; 99:1160-1174.
11. Naveau S, Raynard B, Ratziu V, et al. Biomarkers for the prediction of liver fibro-sis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol 2005; 3:167-174.
12. Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of Peginterferon Alfa-2b and Ribavirin. Hepatology 2003; 38:481-492.
13. Lim AK, Patel N, Hamilton G, Hajnal JV, Goldin RD, Taylor-Robinson SD. The relationship of in vivo P-31 MR spectros-copy to histology in chronic hepatitis C. Hepatology 2003; 37:788.
14. Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elas-tography, fibrotest, APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128:343-350.
15. Aubé C, Racineux PX, Lebigot J, et al. Diagnosis and quantification of hepatic fibrosis with diffusion weighted MR imaging: preliminary results. J Radiol 2004; 85:717-719.
16. Boulanger Y, Amara M, Lepanto L, et al. Diffusion-weighted MR imaging of the liver of hepatitis C patients. NMR Biomed 2003; 16:132-136.
17. Amano Y, Kumazaki T, Ishihara M. Singleshot diffusion-weighted echo-planar imaging of normal and cirrhotic livers using a phased-array multicoil. Acta Radiol 1998; 39:440-442.
18. Kim T, Murakami T, Takahashi S, Hori M, Tsuda K, Nakamura H. Diffusion-weighted single-shot echoplanar MR imaging for liver disease. AJR 1999; 173:393-398.
19. Koinuma M, Ohashi I, Hanafusa K, Shibuya H. Apparent diffusion coefficient measurements with diffusion-weighted magnetic resonance imaging for evaluation of hepatic fibrosis. J Magn Reson Imaging 2005; 22:80-85.
20. Ito K, Mitchell DG, Gabata T. Enlargement of hilar periportal space: a sign of early cirrhosis at MR imaging. J Magn Reson Imaging 2000; 11:136-140.
21. Le Bihan D, Turner R, Douek P, Patronas N. Diffusion MR imaging: clinical applications. AJR 1992; 159:591-599.
22. Le Bihan D. Molecular diffusion, tissue microdynamics and microstructure. NMR Biomed 1995; 8:375-386.
23. Nasu K, Kuroki Y, Sekiguchi R, Kazama T, Nakajima H. Measurement of the apparent diffusion coefficient in the liver: is it a reliable index for hepatic disease diagnosis? Radiat Med 2006; 24:438-444.
24. Naganawa S, Kawai H, Fukatsu H, et al. Diffusion weighted imaging of the liver: technical challenges and prospects for the future. Magn Reson Med Sci 2005; 4:175-186.
25. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histologi-cal activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1:431-435.
26. Yurdaydin C. Entecavir: a step forward in combating hepatitis B disease. Expert Opinion on Pharmacotherapy 2008; 9:3095-3109.
27. Kamal SM, El Tawil AA, Nakano T, et al. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 2005; 54:858-866.
28. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T; MULTIVIRC Group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357:1069-1075.
29. Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41:48-54.
30. Rouvière O, Yin M, Dresner MA, et al. MR elastography of the liver: preliminary results. Radiology 2006; 240:440-448.
31. Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elas-tography, FibroTest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128:343-350.
32. Annet L, Materne R, Danse E, Jamart J, Horsmans Y, Van Beers BE. Hepatic flow parameters measured with MR imaging and Doppler US: correlations with degree of cirrhosis and portal hypertension. Radiology 2003; 229:409-414.
33. Hagiwara M, Rusinek H, Lee VS, et al. Quantification of liver fibrosis in patients with chronic liver disease using 3D per-fusion-weighted MR imaging: preliminary experience. Radiology 2008; 246:926-34.
34. Hsu FO, Chiou YY, Chen CY, et al. Diffusion-weighted magnetic resonance imaging of the liver in hepatitis B patients with Child-Pugh a cirrhosis. Kaohsiung J Med Sci 2007; 23:442-446.
35. Annet L, Peeters F, Abarca-Quinones J, Leclercq I, Moulin P, Van Beers BE. Assessment of diffusion-weighted MR imaging in liver fibrosis. J Magn Reson Imaging 2007; 25:122-128.
36. Geschwind JF, Artemov D, Abraham S, et al. Chemoembolization of liver tumor in a rabbit model: assessment of tumor cell death with diffusion-weighted MR imaging and histologic analysis. J Vasc Interv Radiol 2000; 1:1245-55.
37. Girometti R, Furlan A, Bazzocchi M, et al. Diffusion-weighted MRI in evaluating liver fibrosis: a feasibility study in cirrhotic patients. Radiol Med (Torino) 2007; 112:394-408.
38. Taouli B, Tolia AJ, Losada M, et al. Diffusion-weighted MRI for quantification of liver fibrosis: preliminary experience. AJR 2007; 189:799-806.
39. Hollingsworth KG, Lomas DJ. Influence of perfusion on hepatic MR diffusion measurement. NMR Biomed 2006; 19:231-235.
40. Heintges T, Mohr L, Hensel F, et al. Value of liver biopsy prior to interferon therapy for chronic viral hepatitis. Dig Dis Sci 1998; 43:1562-1565.
41. Norris DG. The effects of microscopic tissue parameters on the diffusion weighted magnetic resonance imaging experiment. NMR Biomed 2001; 14:77-93.
42. Van Beers BE, Materne R, Annet L, et al. Capillarization of the sinusoids in liver fi-brosis: noninvasive assessment with con-trastenhanced MRI in the rabbit. Magn Reson Med 2003; 49:692-699.
43. Yang ZH, Ye XH, Tan Y, et al. Evaluation of cirrhotic liver with perfusion-weighted magnetic resonance imaging: a preliminary experimental study in animal models with half-liver cirrhosis. Chin Med Sci J 2006; 21:252-257.
44. Guan S, Zhou KR, Zhao WD, Peng WJ, Tang F, Mao J. Magnetic resonance diffusion-weighted imaging in the diagnosis of diffuse liver diseases in rats. Chin Med J 2005; 118:639-644.
45. Ito K, Mitchell DG, Hann HW, et al. Progressive viral-induced cirrhosis: serial MR imaging findings and clinical correlation. Radiology 1998; 207:729-735.
46. Zhou XP, Lu T, Wei YG, Chen XZ. Liver volume variation in patients with virus-induced cirrhosis: findings on MDCT. AJR Am J Roentgenol 2007; 189:153-159.
47. Lewin M, Poujol-Robert A, Boëlle PY, et al. Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C. Hepatology 2007; 46:658-665.